Shares Investor Evening (London) - 13 February 2018

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London. Directors from London Stock Exchange listed companies will present their latest plans regarding development and growth, you will have also have the opportunity to talk directly to the Directors and put forward your questions.

Medaphor (MED) - MedaPhor the intelligent ultrasound software and simulation company, develops advanced hi-fidelity ultrasound training simulators, artificial intelligence (AI) image analysis software and augmented reality (AR) needle guidance systems for medical practitioners.

Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:

Ultrasound Simulation and Training which focuses on hi-fidelity ultrasound education and training through simulation. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Ultrasound Clinical Support which focuses on developing AI algorithms to make ultrasound machines smarter and more accessible.

Plutus PowerGen (PPG) - Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver.

Plutus PowerGen has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UKs power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGens projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading Big Six multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward.

PrimaryBid - PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings from companies listed on UK Stock Exchanges. Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares. More than £55m has been sourced via the platform and some recent offers have closed within hours. Its free to join, with no obligation to participate in any offer, just visit www.primarybid.com & create your account.

Rockhopper Exploration (RKH) - Rockhopper is an AIM listed oil and gas company based in the UK with interests in the Falkland Islands and the Greater Mediterranean region. Rockhoppers strategy is to build a well-funded, full-cycle, exploration led E&P company.

The Company is the leading acreage holder in the North Falkland Basin with independently audited 2C oil resources, net to Rockhopper, in excess of 250 mmbbl.

Through a series of acquisition and organic growth initiatives, Rockhopper has built a portfolio of production and exploration assets in the Greater Mediterranean which produced approximately 1,350 boepd during 2016 and is expected to generate material future exploration activity.

Valirx (VAL) - Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Companys proprietary technology platform, GeneICE, enables selective silencing of rebellious genes inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.